Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Buttò S, Monini P, Ensoli B.

Vaccines (Basel). 2019 Aug 26;7(3). pii: E99. doi: 10.3390/vaccines7030099. Review.

2.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B.

Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.

3.
4.

"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".

Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B.

Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.

PMID:
29243498
5.

Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.

Bacigalupo I, Palladino C, Leone P, Toschi E, Sgadari C, Ensoli B, Barillari G.

Oncol Lett. 2017 May;13(5):2903-2908. doi: 10.3892/ol.2017.5835. Epub 2017 Mar 9.

6.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

7.

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.

Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B.

Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.

PMID:
26096836
8.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

9.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

10.

The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.

Barillari G, Iovane A, Bacigalupo I, Labbaye C, Chiozzini C, Sernicola L, Quaranta MT, Falchi M, Sgadari C, Ensoli B.

Angiogenesis. 2014 Oct;17(4):831-8. doi: 10.1007/s10456-014-9430-9. Epub 2014 Apr 10.

PMID:
24719186
11.

Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a.

Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caprara L, Barillari G, Monini P, Nannini R, Ensoli B, Bucchi L.

Int J Gynecol Cancer. 2013 Nov;23(9):1663-9. doi: 10.1097/IGC.0b013e3182a80b14.

PMID:
24172101
12.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

13.

Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.

Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B, Toschi E, Ensoli B.

Int J Vasc Med. 2011;2011:452729. doi: 10.1155/2011/452729. Epub 2011 Oct 9.

14.

Pharmacological management of Kaposi's sarcoma.

Sgadari C, Bacigalupo I, Barillari G, Ensoli B.

Expert Opin Pharmacother. 2011 Aug;12(11):1669-90. doi: 10.1517/14656566.2011.577066. Epub 2011 Apr 25. Review.

PMID:
21517697
15.

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B.

Int J Cancer. 2011 Jan 1;128(1):82-93. doi: 10.1002/ijc.25550.

16.

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli B.

Int Rev Immunol. 2009;28(5):285-334. doi: 10.1080/08830180903013026. Review.

PMID:
19811313
17.

Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.

Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B.

AIDS. 2009 Feb 20;23(4):534-8. doi: 10.1097/QAD.0b013e3283262a8d.

PMID:
19169139
18.

The use of HAART for biological tumour therapy.

Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, Ensoli B.

J HIV Ther. 2006 Sep;11(3):53-6. Review. No abstract available.

PMID:
17580499
19.

Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.

Buffa V, Negri DR, Leone P, Borghi M, Bona R, Michelini Z, Compagnoni D, Sgadari C, Ensoli B, Cara A.

Viral Immunol. 2006 Winter;19(4):690-701.

PMID:
17201664
20.

A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.

Buffa V, Negri DR, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A.

J Gen Virol. 2006 Jun;87(Pt 6):1625-34.

PMID:
16690927
21.

Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.

Simonelli C, Talamini R, Bearz A, Berretta M, Spazzapan S, Monini P, Sgadari C, Sartor I, Ensoli B, Tirelli U.

Ann Oncol. 2006 Aug;17(8):1335-6. Epub 2006 Mar 28. No abstract available.

PMID:
16569648
22.

HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway.

Toschi E, Bacigalupo I, Strippoli R, Chiozzini C, Cereseto A, Falchi M, Nappi F, Sgadari C, Barillari G, Mainiero F, Ensoli B.

Mol Biol Cell. 2006 Apr;17(4):1985-94. Epub 2006 Jan 25.

23.

Antitumour effects of antiretroviral therapy.

Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B.

Nat Rev Cancer. 2004 Nov;4(11):861-75. Review.

PMID:
15516959
24.

HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells.

Franzese O, Comandini A, Adamo R, Sgadari C, Ensoli B, Bonmassar E.

Cell Death Differ. 2004 Jul;11(7):782-4. No abstract available.

25.

Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

Sgadari C, Monini P, Barillari G, Ensoli B.

Lancet Oncol. 2003 Sep;4(9):537-47. Review.

PMID:
12965274
26.

HIV protease inhibitors as new treatment options for Kaposi's sarcoma.

Barillari G, Sgadari C, Toschi E, Monini P, Ensoli B.

Drug Resist Updat. 2003 Aug;6(4):173-81.

PMID:
12962683
27.

[HIV protease inhibitors for the treatment of Kaposi's sarcoma].

Grosso G, Sgadari C, Barillari G, Toschi E, Bacigalupo I, Carlei D, Palladino C, Baccarini S, Malavasi L, Moracci G, Leone P, Chiozzini C, Monini P, Ensoli B.

Recenti Prog Med. 2003 Feb;94(2):69-74. Review. Italian.

PMID:
12908373
28.

HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.

Monini P, Sgadari C, Barillari G, Ensoli B.

J Antimicrob Chemother. 2003 Feb;51(2):207-11. Review. No abstract available.

PMID:
12562682
29.

Treatment of Kaposi's sarcoma--an update.

Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, Palladino C, Baccarini S, Carlei D, Grosso G, Sirianni MC, Ensoli B.

Anticancer Drugs. 2002 Nov;13(10):977-87. Review.

PMID:
12439331
30.

Identification of the hemangioblast in postnatal life.

Pelosi E, Valtieri M, Coppola S, Botta R, Gabbianelli M, Lulli V, Marziali G, Masella B, Müller R, Sgadari C, Testa U, Bonanno G, Peschle C.

Blood. 2002 Nov 1;100(9):3203-8.

PMID:
12384418
31.

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.

Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B.

Nat Med. 2002 Mar;8(3):225-32.

PMID:
11875492
32.

Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report.

Monini P, Sirianni MC, Franco M, Vincenzi L, Topino S, Goletti D, Leone P, Leone P, Chiozzini C, Nicastri E, Andreoni M, Borduagni O, Sgadari C, Rezza G, Stürzl M, Ensoli B.

Clin Infect Dis. 2001 Nov 15;33(10):1782-5. Epub 2001 Oct 12.

PMID:
11641829
33.

Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.

Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, Palladino C, Zietz C, Leone P, Stürzl M, Buttò S, Cafaro A, Monini P, Ensoli B.

Mol Biol Cell. 2001 Oct;12(10):2934-46.

34.

Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability.

Ascherl G, Sgadari C, Bugarini R, Bogner J, Schatz O, Ensoli B, Stürzl M.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1035-9.

PMID:
11485620
35.

Biology of Kaposi's sarcoma.

Ensoli B, Sgadari C, Barillari G, Sirianni MC, Stürzl M, Monini P.

Eur J Cancer. 2001 Jul;37(10):1251-69. Review.

PMID:
11423257
36.

Interleukin-18 expression induced by Epstein-Barr virus-infected cells.

Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G.

J Leukoc Biol. 2001 May;69(5):779-84.

PMID:
11358987
37.

Treatment update for AIDS-related Kaposi's sarcoma.

Mihalcea AM, Smith DL, Monini P, Sgadari C, Ensoli B, Gill PS.

AIDS. 1999;13 Suppl A:S215-25. Review. No abstract available.

PMID:
10885778
38.

Mechanism of paclitaxel activity in Kaposi's sarcoma.

Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, Yarchoan R, Monini P, Stürzl M, Ensoli B.

J Immunol. 2000 Jul 1;165(1):509-17.

39.

Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin.

Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, Nair BC, Markham P, Nel A, Stürzl M, Ensoli B.

J Immunol. 1999 Aug 15;163(4):1929-35.

40.

The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor.

Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Stürzl M, Ensoli B.

Blood. 1999 Jul 15;94(2):663-72.

PMID:
10397733
41.

Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma.

Monini P, Colombini S, Stürzl M, Goletti D, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Ascherl G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, Yarchoan R, Gallo RC, Ensoli B.

Blood. 1999 Jun 15;93(12):4044-58.

PMID:
10361101
42.

Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Monini P, Carlini F, Stürzl M, Rimessi P, Superti F, Franco M, Melucci-Vigo G, Cafaro A, Goletti D, Sgadari C, Butto' S, Leone P, Chiozzini C, Barresi C, Tinari A, Bonaccorsi A, Capobianchi MR, Giuliani M, di Carlo A, Andreoni M, Rezza G, Ensoli B.

J Virol. 1999 May;73(5):4029-41.

43.

Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12.

Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G.

Blood. 1999 Mar 1;93(5):1612-21.

PMID:
10029590
44.
45.

Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12.

Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L, Tosato G.

J Leukoc Biol. 1998 Sep;64(3):384-92.

PMID:
9738666
46.

Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo.

Cherney BW, Sgadari C, Kanegane C, Wang F, Tosato G.

Blood. 1998 Apr 1;91(7):2491-500.

PMID:
9516150
47.

Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.

Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G.

Cancer Res. 1997 Jun 15;57(12):2508-15.

48.

Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo.

Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G.

Blood. 1997 Apr 15;89(8):2635-43.

PMID:
9108380
49.

Interleukin-15 promotes angiogenesis in vivo.

Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G.

Biochem Biophys Res Commun. 1997 Apr 7;233(1):231-7.

PMID:
9144429
50.

Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.

Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6.

Supplemental Content

Loading ...
Support Center